| ［1］ |
Hardy WR, Anderson RE. The hypereosinophilic syndromes［J］. Ann Intern Med, 1968,68（6）:1220⁃1229. DOI: 10.7326/0003⁃4819⁃68⁃6⁃1220.
|
| ［2］ |
Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature［J］. Medicine （Baltimore）, 1975,54（1）:1⁃27.
|
| ［3］ |
Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome［J］. J Allergy Clin Immunol, 2010,126（1）:45⁃49. DOI: 10.1016/j.jaci.2010.03.042.
|
| ［4］ |
Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes［J］. J Allergy Clin Immunol, 2012,130（3）:607⁃612.e9. DOI: 10.1016/j.jaci.2012.02.019.
|
| ［5］ |
Shomali W, Gotlib J. World Health Organization⁃defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management［J］. Am J Hematol, 2022,97（1）:129⁃148. DOI: 10.1002/ajh.26352.
|
| ［6］ |
Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes［J］. Allergy, 2023,78（1）:47⁃59. DOI: 10.1111/all.15544.
|
| ［7］ |
Pineton de Chambrun G, Desreumaux P, Cortot A. Eosinophilic enteritis［J］. Dig Dis, 2015,33（2）:183⁃189. DOI: 10.1159/0003 69540.
|
| ［8］ |
Brambatti M, Matassini MV, Adler ED, et al. Eosinophilic myocarditis: characteristics, treatment, and outcomes［J］. J Am Coll Cardiol, 2017,70（19）:2363⁃2375. DOI: 10.1016/j.jacc. 2017.09.023.
|
| ［9］ |
Tennenbaum J, Groh M, Venditti L, et al. FIP1L1⁃PDGFRA⁃associated hypereosinophilic syndrome as a treatable cause of watershed infarction［J］. Stroke, 2021,52（10）:e605⁃e609. DOI: 10.1161/STROKEAHA.121.034191.
|
| ［10］ |
Valent P, Klion AD, Rosenwasser LJ, et al. ICON: eosinophil disorders［J］. World Allergy Organ J, 2012,5（12）:174⁃181. DOI: 10.1097/WOX.0b013e31827f4192.
|
| ［11］ |
Zayas J, Peters MS, Butterfield JH, et al. Clinical and histopathological features of hypereosinophilic syndrome with cutaneous involvement: the Mayo Clinic Experience［J］. J Cutan Pathol, 2023,50（5）:455⁃465. DOI: 10.1111/cup.14410.
|
| ［12］ |
Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report［J］. J Allergy Clin Immunol, 2006,117（6）:1292⁃1302. DOI: 10.1016/j.jaci.2006.02.042.
|
| ［13］ |
Akuthota P, Weller PF. Spectrum of eosinophilic end⁃organ manifestations［J］. Immunol Allergy Clin North Am, 2015,35（3）:403⁃411. DOI: 10.1016/j.iac.2015.04.002.
|
| ［14］ |
Curtis C, Ogbogu P. Hypereosinophilic syndrome［J］. Clin Rev Allergy Immunol, 2016,50（2）:240⁃251. DOI: 10.1007/s12016⁃015⁃8506⁃7.
|
| ［15］ |
Helbig G, Klion AD. Hypereosinophilic syndromes ⁃ an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment［J］. Blood Rev, 2021,49:100809. DOI: 10.1016/j.blre.2021.100809.
|
| ［16］ |
Weller PF, Spencer LA. Functions of tissue⁃resident eosinophils［J］. Nat Rev Immunol, 2017,17（12）:746⁃760. DOI: 10.1038/nri. 2017.95.
|
| ［17］ |
Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field［J］. Expert Rev Hematol, 2012,5（2）:157⁃176. DOI: 10.1586/ehm.11.81.
|
| ［18］ |
Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease［J］. Annu Rev Pathol, 2020,15:179⁃209. DOI: 10.1146/annurev⁃pathmechdis⁃012419⁃032756.
|
| ［19］ |
Fulkerson PC, Rothenberg ME. Eosinophil development, disease involvement, and therapeutic suppression［J］. Adv Immunol, 2018,138:1⁃34. DOI: 10.1016/bs.ai.2018.03.001.
|
| ［20］ |
Moussiegt A, Müller R, Ebbo M, et al. IgG4⁃related disease and hypereosinophilic syndrome: overlapping phenotypes［J］. Autoimmun Rev, 2021,20（9）:102889. DOI: 10.1016/j.autrev.2021.102889.
|
| ［21］ |
Khoury P, Herold J, Alpaugh A, et al. Episodic angioedema with eosinophilia （Gleich syndrome） is a multilineage cell cycling disorder［J］. Haematologica, 2015,100（3）:300⁃307. DOI: 10. 3324/haematol.2013.091264.
|
| ［22］ |
Carpentier C, Schandené L, Dewispelaere L, et al. CD3（⁃）CD4（+） lymphocytic variant hypereosinophilic syndrome: diagnostic tools revisited［J］. J Allergy Clin Immunol Pract, 2021,9（6）:2426⁃2439.e7. DOI: 10.1016/j.jaip.2021.01.030.
|
| ［23］ |
Ledoult E, Groh M, Kahn JE, et al. Assessment of T⁃cell polarization on the basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome［J］. J Allergy Clin Immunol Pract, 2020,8（3）:1110⁃1114.e2. DOI: 10.1016/j.jaip.2019.08.049.
|
| ［24］ |
Carpentier C, Verbanck S, Schandené L, et al. Eosinophilia associated with CD3（⁃）CD4（+） T cells: characterization and outcome of a single⁃center cohort of 26 patients［J］. Front Immunol, 2020,11:1765. DOI: 10.3389/fimmu.2020.01765.
|
| ［25］ |
Shi Y, Wang C. What we have learned about lymphocytic variant hypereosinophilic syndrome: a systematic literature review［J］. Clin Immunol, 2022,237:108982. DOI: 10.1016/j.clim.2022. 108982.
|
| ［26］ |
Hwee J, Huynh L, Du S, et al. Hypereosinophilic syndrome in Europe: retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization［J］. Ann Allergy Asthma Immunol, 2023,130（6）:768⁃775. DOI: 10.1016/j.anai.2023.02.022.
|
| ［27］ |
Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1⁃PDGFRalpha⁃positive hypereosinophilic syndrome. Results of a multicenter prospective study［J］. Haematologica, 2007,92（9）:1173⁃1179. DOI: 10.3324/haematol.11420.
|
| ［28］ |
Groh M, Rohmer J, Etienne N, et al. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes［J］. Orphanet J Rare Dis, 2023,18（1）:100. DOI: 10.1186/s13023⁃023⁃02696⁃4.
|
| ［29］ |
Klion A. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine［J］. Hematology Am Soc Hematol Educ Program, 2018,2018（1）:326⁃331. DOI: 10.1182/asheducation⁃ 2018.1.326.
|
| ［30］ |
Panch SR, Bozik ME, Brown T, et al. Dexpramipexole as an oral steroid⁃sparing agent in hypereosinophilic syndromes［J］. Blood, 2018;132（5）:501⁃509. DOI: 10.1182/blood⁃2018⁃08⁃870204.
|
| ［31］ |
Menigoz C, Dirou S, Chambellan A, et al. Use of FeNO to predict anti⁃IL⁃5 and IL⁃5R biologics efficacy in a real⁃world cohort of adults with severe eosinophilic asthma［J］. J Asthma, 2023,60（6）:1162⁃1170. DOI: 10.1080/02770903.2022.2136526.
|
| ［32］ |
Khoury P, Abiodun AO, Holland⁃Thomas N, et al. Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids［J］. J Allergy Clin Immunol Pract, 2018,6（1）:190⁃195. DOI: 10.1080/02770903.2022.2136526.
|
| ［33］ |
Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia［J］. Clin Cancer Res, 2009,15（1）:368⁃373. DOI: 10. 1158/1078⁃0432.CCR⁃08⁃1302.
|
| ［34］ |
Iurlo A, Cattaneo D. Biologic therapies for hypereosinophilic disorders: from tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?［J］. Blood Rev, 2023,58:101014. DOI: 10.1016/j.blre.2022.101014.
|
